Erectile function (EF)

Erectile function is a complex physiological process involving a coordinated interplay between psychological, neural, vascular, and endocrine systems that results in penile tumescence and rigidity (PMID: 29763006). The process is primarily initiated by the release of nitric oxide (NO) from non-cholinergic, non-adrenergic (NANC) nerve terminals and vascular endothelial cells within the corpus cavernosum. This NO activates the enzyme soluble guanylate cyclase (sGC), which catalyzes the conversion of GTP to cyclic guanosine monophosphate (cGMP), leading to a reduction in intracellular calcium and subsequent relaxation of cavernous smooth muscle (StatPearls, NBK562253). This relaxation allows for increased blood flow into the lacunar spaces and the compression of emissary veins, maintaining the erection. Because erectile function is a systemic physiological response rather than a discrete protein or receptor, it is not classified as a molecular therapeutic target; however, specific molecules within its pathway, such as Phosphodiesterase type 5 (PDE5), are high-value targets for treating erectile dysfunction (PMID: 15339631). Common pharmacological interventions modulate this function by inhibiting the degradation of cGMP or by serving as prostaglandin analogs to bypass impaired NO signaling (PubMed, 22216641).

Other names

Penile erectionErectile physiological processSexual arousal responseMale erectile response

Inhibition of Phosphodiesterase type 5 (PDE5) to increase cGMP levels; Agonism of Prostaglandin E1 (PGE1) receptors to stimulate adenylate cyclase; Antagonism of alpha-adrenergic receptors (PMID: 15339631; StatPearls, NBK562253).